The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TYRA | -5.04% | N/A | N/A | -39% |
| S&P | +19.89% | +109.18% | +15.89% | +53% |
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.14M | -11.1% |
| Market Cap | $508.91M | -39.3% |
| Market Cap / Employee | $8.48M | 0.0% |
| Employees | 60 | 22.4% |
| Net Income | -$28.10M | -50.2% |
| EBITDA | -$31.31M | -33.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $98.49M | -1.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.58M | -7.2% |
| Short Term Debt | $0.44M | 15.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -29.65% | -4.5% |
| Return On Invested Capital | -30.84% | -22.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.71M | -121.0% |
| Operating Free Cash Flow | -$23.68M | -130.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 3.30 | 2.03 | 1.38 | 1.57 | -27.03% |
| Price to Tangible Book Value | 3.30 | 2.03 | 1.38 | 1.57 | -27.03% |
| Enterprise Value to EBITDA | -36.18 | -16.41 | -7.54 | -8.93 | -63.37% |
| Return on Equity | -28.7% | -31.6% | -27.0% | -31.2% | 18.59% |
| Total Debt | $6.32M | $6.22M | $6.12M | $6.02M | -5.88% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
